title: Posterior capsule opacification in eyes with steroid-induced cataracts: Comparison of early results.
abstract: OBJECTIVE
  To evaluate posterior capsule opacification (PCO) development after cataract surgery in eyes with or without a history of steroid use.
  
  
  METHODS
  Iladevi Cataract & IOL Research Centre, Ahmedabad, India.
  
  
  METHODS
  Comparative case series.
  
  
  METHODS
  This study comprised consecutive patients with a history of steroid intake (oral, inhaled, injectable, or topical) for at least 4 months who developed posterior subcapsular cataract (PSC) (study group) and patients without a history of steroid intake with uncomplicated PSC (control group). Standardized surgery was performed in both groups. Digital retroillumination photographic documentation was performed 1 month and 1 year postoperatively. The digital images were analyzed for PCO using Evaluation of Posterior Capsule Opacification (EPCO) software; the entire intraocular lens (IOL) optic and the central 3.0 mm optic area were evaluated. The EPCO score and EPCO area were determined.
  
  
  RESULTS
  One year postoperatively, the mean EPCO score was statistically significantly higher in the study group (n = 30) than in the control group (n = 60) (0.33 ± 0.37 [SD] versus 0.15 ± 0.26), as was the mean EPCO area (0.323 ± 0.36 versus 0.15 ± 0.26) (both P<.04). Within the central 3.0 mm optic area, the mean EPCO scores (0.149 ± 0.309 versus 0.003 ± 0.016 P<.04) and mean EPCO area values (0.149 ± 0.309 versus 0.003 ± 0.016) were statistically significantly higher in the study group (P<.04).
  
  
  CONCLUSIONS
  Steroid-induced PSC was associated with a higher risk for PCO after cataract surgery at the 1-year follow-up.
  
  
  BACKGROUND
  No author has a financial or proprietary interest in any material or method mentioned.
authors.affiliation: Iladevi Cataract & IOL Research Center, Raghudeep Eye Clinic, Gurukul Road, Memnagar, Ahmedabad, India.
authors.forename: Mamidipudi R
authors.initials: MR
authors.lastname: Praveen
authors.forename: Gauri D
authors.initials: GD
authors.lastname: Shah
authors.forename: Abhay R
authors.initials: AR
authors.lastname: Vasavada
authors.forename: Alpesh R
authors.initials: AR
authors.lastname: Shah
authors.forename: Kaid
authors.initials: K
authors.lastname: Johar
authors.forename: Yogesh
authors.initials: Y
authors.lastname: Gami
authors.forename: Rasesh P
authors.initials: RP
authors.lastname: Diwan
authors.forename: Shubhangi M
authors.initials: SM
authors.lastname: Shah
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D001249:Asthma / Q000188:drug therapy; D016022:Case-Control Studies; D002386:Cataract / Q000139:chemically induced*; D005128:Eye Diseases / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D018918:Phacoemulsification; D057852:Posterior Capsule of the Lens / Q000187:drug effects* / Q000473:pathology; D011446:Prospective Studies; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D005938:Glucocorticoids